Molecular Insight: Court continues disclosure statement hearing

By Lisa Kerner

Charlotte, N.C., Feb. 22 - Molecular Insight Pharmaceuticals, Inc.'s Feb. 25 hearing to approve its disclosure statement was continued, according to a Monday filing with the U.S. Bankruptcy Court for the District of Massachusetts.

The hearing will be rescheduled at a later date, the filing said.

As previously reported, the company filed its plan of reorganization and related disclosure statement on Feb. 3.

Molecular Insight, a Cambridge, Mass.-based clinical-stage biopharmaceutical company focused on molecular medicine, filed for bankruptcy on Dec. 9, 2010. The Chapter 11 case number is 10-23355.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.